Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells

• US 20060188499A1
• Filed: 02/14/2006
• Published: 08/24/2006
• Est. Priority Date: 02/14/2005
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company), National Jewish Medical and Research Center
• Original Assignee: National Jewish Medical and Research Center
• Inventors: Bilsborough, Janine, Gross, Jane A., Leung, Donald Y.M.
• Application Number:
  US11/353,427
• Publication Number:
  US 20060188499A1
• Time in Patent Office: Days
• US Class Current: 424/143.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61K 49/006 Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 33/505 involving T-cells
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: G01N 33/6881 : from skin

Abstract

The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.

Claims

1. A method of treating diseased skin comprising administering an antagonist molecule to a mammal with the diseased skin wherein the diseased skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2 or SEQ ID NO;

4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin.

2. The method according to claim 1, wherein the patient has a skin disorder selected from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, and Herpes simplex virus.

3. The method according to claim 2, wherein the mammal is a human.

4. The method according to claim 1, wherein the antagonist is an antibody or antibody fragment.

5. The method according to claim 4, wherin the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2.

6. The method according to claim 1, wherein the diseased skin is pruritic.

7. A method for treating pruritis comprising administering an antagonist molecule to a mammal with the pruritis wherein the pruritis is characterized by cutaneous lymphocyte antigen positive T cells and wherein the antagonist molecule specifically binds to the polypeptide having the amino acid sequence as shown in SEQ ID NO:

2 or in SEQ ID NO;

4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the pruritis.

8. The method according to claim 7, wherein the pruritis is associated with a skin disorder selected from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, and Herpes simplex virus.

9. The method according to claim 8, wherein the mammal is a human.

10. The method according to claim 7, wherein the antagonist is an antibody or antibody fragment.

11. The method according to claim 10, wherin the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2.

17. The method according to claim 10, comprising the additional step of stimulating or activating the cutaneous lymphocyte antigen positive T cells.

18. The method according to claim 17, wherein the IL-31 is detected by specifically binding to an IL-31 antagonist.

19. The method according to claim 17, wherein the IL-31 antagonist molecule is an anti-IL-31 antibody or antibody fragment.

20. The method according to claim 19, wherin the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2.

12. A method for predicting therapeutic response to an IL-31 antagonist in an individual in need of IL-31 antagonist therapy comprising obtaining a biological sample from the patient, isolating circulating cutaneous lymphocyte positive T cells from the biological sample, and detecting IL-31 production from the isolated cutaneous lymphocyte positive T cells.

13. The method according to claim 12, wherein the IL-31 is detected by specifically binding to an IL-31 antagonist.

14. The method according to claim 13, wherein the IL-31 antagonist is an anti-IL-31 antibody or antibody fragment.

15. The method according to claim 12, wherin the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2.

16. The method according to claim 12, wherein the individual in need of IL-31 antagonist therapy has a skin disorder selected from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, and Herpes simplex virus.